LAUPHEIM and RAVENSBURG, Germany, MILFORD, MA, and SKOKIE, IL, USA, March 29, 2022 / B3C newswire / Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), announced today that the companies are unveiling Xpert Alliance, a joint visualizati.
Investegate announcements from Rentschler Biopharma SE, Rentschler Biopharma appoints Dr. Robert Panting as General Manager of Rentschler ATMP Ltd., Center of Excellence for Cell and Gene Therapy
Rentschler Biopharma and XL-protein have teamed up on the manufacture of what they say is a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I) that may open better treatment options for patients suffering from inflammation, chronic or autoimmune diseases.